PAYS earnings

Mix Shift Continues to Deliver Expansion in Gross and Operating Margin Strong Balance Sheet Enables Continued Investment for Profitable Growth Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability offerings, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced financial results for the first quarter 2026. First Quarter 2026 Financial Highlights First quarter 2026 revenues of $28.04 million, up 50.8% from first quarter 2025 First quarter 2026 pharma revenue increased to $15.68 million, an increase of 81.9% versus first quarter 2025; added 45 net patient affordabili

Mix Shift Drives Gross and Operating Margin Expansion Strong Balance Sheet Enables Continued Investment for Profitable Growth Paysign, Inc. (NASDAQ:PAYS), a leading provider of patient affordability offerings, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced financial results for the fourth quarter and full-year 2025. Full-Year Financial Highlights Full-year 2025 total revenues of $82.0 million, up 40.5% from 2024 Total net plasma center count increased by 115 during 2025, exiting the year with 595 centers, contributing to a 4.0% increase in plasma revenue versus the same period

Delivered strong performance with record revenue and improved profitability Third quarter 2025 total revenues of $21.60 million, up 41.6% from third quarter 2024 Third quarter 2025 net income of $2.22 million, up 54.2% from $1.44 million a year ago, while diluted earnings per share was $0.04 versus $0.03 for third quarter 2024 Third quarter 2025 Adjusted EBITDA of $5.04 million (23.3% of revenues), up 78.1% from $2.83 million (18.5% of revenues) a year ago, while diluted Adjusted EBITDA per share was $0.08 versus $0.05 for third quarter 20241 Year-over-year plasma revenue increased 12.4% to $12.86 million; exited the quarter with 595 plasma centers, an increase of 117 plasma ce

Second quarter 2025 total revenues of $19.08 million, up 33.1% from second quarter 2024 Second quarter 2025 net income of $1.39 million, up 99.1% from $697 thousand a year ago, while diluted earnings per share was $0.02, versus $0.01 for second quarter 2024 Second quarter 2025 Adjusted EBITDA of $4.51 million, up 101.8% from $2.24 million a year ago, while diluted Adjusted EBITDA per share was $0.08 versus $0.04 for second quarter 20241 Added 123 net plasma centers during second quarter 2025, all which went live June 16. We exited the quarter with 607 centers; average monthly revenue per plasma center decreased to $7,098 compared to $7,916 for the same period last year; year-over-

First quarter 2025 total revenues of $18.60 million, up 41.0% from first quarter 2024 First quarter 2025 net income of $2.59 million, or diluted earnings per share of $0.05, versus net income of $309 thousand, or diluted earnings per share of $0.01, for first quarter 2024 First quarter 2025 Adjusted EBITDA of $4.96 million, up 193.3% from $1.69 million a year ago, while diluted Adjusted EBITDA per share was $0.09 versus $0.03 for first quarter 20241 Total plasma center count increased by four net centers during first quarter 2025, exiting the quarter with 484 centers; revenue per plasma center decreased to $6,517 compared to $7,414 for the same period last year; year-over-year plasma

For the Full-Year Full-year 2024 total revenues of $58.38 million, up 23.5% from full-year 2023 Full-year 2024 net income of $3.82 million, or diluted earnings per share of $0.07, versus net income of $6.46 million, or diluted earnings per share of $0.12 for full-year 2023 Full-year 2024 Adjusted EBITDA of $9.62 million, up 43.3% from $6.71 million a year ago, while diluted Adjusted EBITDA per share was $0.17 versus $0.12 for full-year 20231 Total plasma center count increased by 16 during 2024, exiting the year with 480 centers, contributing to a 4.6% increase in plasma revenue versus the same period last year Added 33 net patient affordability programs during 2024, exiting the y

Second quarter 2024 total revenues of $14.33 million, up 29.8% from second quarter 2023 Second quarter 2024 net income of $697 thousand, or diluted earnings per share of $0.01, versus net loss of $104 thousand, or diluted earnings per share of $(0.00) for second quarter 2023 Second quarter 2024 Adjusted EBITDA of $2.24 million, up 95.8% from $1.14 million for second quarter 2023, while diluted Adjusted EBITDA per share was $0.04 versus $0.02 for second quarter 20231 Total plasma center count increased by eight net new centers during second quarter 2024, exiting the quarter with 477 centers, contributing to a 12.6% increase in plasma revenue versus the same period last year Adde

First quarter 2024 total revenues of $13.2 million, up 30% from first quarter 2023First quarter 2024 net income of $309 thousand, or diluted earnings per share of $0.01, versus net loss of $160 thousand, or diluted earnings per share of $(0.00) for first quarter 2023First quarter 2024 Adjusted EBITDA of $1.7 million, up 135% from $720 thousand for first quarter 2023, while diluted Adjusted EBITDA per share was $0.03 versus $0.01 for first quarter 20231Total plasma center count increased by five net new centers during first quarter 2024, exiting the quarter with 469 centers, contributing to an 11% increase in plasma revenue versus the same period last yearAdded 10 net new patient affordabilit

For the Full YearFull-year 2023 total revenues of $47.3 million, up 24% from full-year 2022Full-year 2023 net income of $6.5 million, or diluted earnings per share of $0.12, versus net income of $1.0 million, or diluted earnings per share of $0.02 for full-year 2022Full-year 2023 Adjusted EBITDA of $6.7 million, up 21% from $5.5 million a year ago, while diluted Adjusted EBITDA per share was $0.12 versus $0.10 for full-year 20221Total plasma center count increased by 20 during 2023, exiting the year with 464 centers, contributing to a 21% increase in plasma revenue versus the same period last yearLaunched 24 net new patient affordability programs during 2023, exiting the year with 43 active

Third quarter total revenues of $12.4 million, an increase of 17% compared to third quarter 2022Third quarter net income of $1.1 million and diluted income per share of $0.02Third quarter Adjusted EBITDA of $2.3 million, an increase of 22% compared to third quarter 2022, and diluted Adjusted EBITDA per share of $0.04, unchanged from third quarter 20221Added 19 net new plasma donation centers during the third quarter, exiting the quarter with 462 centers, leading to a 13% increase in plasma revenue over the same period last yearLaunched three new patient affordability programs during the third quarter, exiting the quarter with 34 active programs, leading to a 142% increase in pharma patient a

Second quarter total revenues of $11.0 million, an increase of 28% compared to second quarter 2022Second quarter net loss of ($0.1) million and diluted loss per share of ($0.00)Second quarter Adjusted EBITDA of $1.1 million, an increase of 23% compared to second quarter 2022, and diluted Adjusted EBITDA per share of $0.02, unchanged from second quarter 2022 (Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business - see reconciliation of net loss to Adjusted EBITDA at the end of the press release)Added four net new plasma donation centers during the second quarter, exiting the quarter with 443 centersLaunched fiv

First quarter total revenues of $10.1 million, up 23% from first quarter 2022First quarter net loss of ($0.2) million, or diluted loss per share of ($0.00)First quarter Adjusted EBITDA of $0.7 million, down 22% from $0.9 million a year ago, while diluted Adjusted EBITDA per share was $0.01 versus $0.02 for the first quarter 2022 (Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business - see reconciliation of net loss to Adjusted EBITDA at the end of the press release)Added 10 plasma donation centers during the first quarter, exiting the quarter with 439 centersLaunched seven new patient affordability programs du

Company's Board Authorizes $5 Million Share Repurchase Program For the Full Year Full-year 2022 total revenues of $38.0 million, up 29% from full-year 2021 Full-year 2022 net income of $1.0 million, or diluted earnings per share of $0.02 Full-year 2022 Adjusted EBITDA of $5.5 million, up 175% from $2.0 million a year ago, while diluted Adjusted EBITDA per share was $0.10 versus $0.04 for full-year 2021 (Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation of Net Income to Adjusted EBITDA at the end of the press release) Added 78 net plasma donation centers during 2022, exiting t

Third quarter total revenues of $10.6 million, an increase of $2.8 million (36.4%) from third quarter 2021 Third quarter net income of $0.85 million, or diluted earnings per share of $0.02 Third quarter Adjusted EBITDA of $1.9 million, or diluted Adjusted EBITDA per share of $0.04 (Adjusted EBITDA is a non-GAAP metric used by management to gauge the operating performance of the business – See reconciliation of Net Income to Adjusted EBITDA at the end of the press release) Added 13 plasma donation centers during the third quarter, bringing the year-to-date total additions to 84 Third quarter gross dollar load volume up 57.6% versus the year-ago period and up 23.1% versus the previou

Second quarter total revenues of $8.6 million, an increase of $1.9 million (29%) from second quarter 2021 Second quarter net loss of $0.2 million, or diluted net loss per share of ($0.00) Second quarter Adjusted EBITDA of $0.9 million, or diluted Adjusted EBITDA per share of $0.02 Added 62 plasma donation centers during the second quarter bringing the first half total additions to 71 Second quarter gross dollar load volume up 40.5% versus the year-ago period and 16.1% versus the previous quarter Second quarter purchase volume was up 45.7% versus the year-ago period and 26.8% versus the previous quarter Engaged Moss Adams LLP as the company's independent registered public accoun

First quarter total revenues of $8.2 million, an increase of $1.9 million from first quarter 2021 First quarter net loss of $0.3 million, or diluted net loss per share of ($0.01) First quarter adjusted EBITDA of $0.9 million, or diluted adjusted EBITDA per share of $0.02 First quarter gross dollar load volume up 16.2% versus the year-ago period and 7.6% versus the previous quarter First quarter purchase volume up 24.7% versus the year-ago period First quarter unrestricted cash increased by $1.1 million to $8.5 million Paysign, Inc. (NASDAQ:PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated p

Fourth quarter total revenues of $8.8 million, an increase of $1.5 million from fourth-quarter 2020 Fourth quarter net income of $0.1 million, or diluted earnings per share (EPS) of $0.00 Fourth quarter adjusted EBITDA of $1.3 million, or diluted adjusted EBITDA per share of $0.02 Fourth quarter gross dollar load volume up 12.5% versus the year-ago period and 4.6% versus the previous quarter Fourth quarter purchase volume up 13.2% versus the year-ago period and up 5.4% versus the previous quarter Paysign, Inc. (NASDAQ:PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today

Third-quarter total revenues of $7.8 million, a year-over-year increase of $7.9 million Third-quarter plasma revenue of $7.0 million, a year-over-year increase of $1.8 million or 35.6% Third-quarter net loss of $0.3 million, or diluted earnings per share (EPS) of ($0.01) Third-quarter adjusted EBITDA of $1.0 million, or diluted adjusted EBITDA per share of $0.02 Third-quarter purchase transactions and purchase dollar volume increased 14.6% and 33.9% year-over-year, respectively Third-quarter total loads and total gross dollar load volume increased 1.9% and 24.7% year-over-year, respectively Paysign, Inc. (NASDAQ:PAYS), a leading provider of prepaid card programs, comprehensive

Second-quarter total loads and total gross dollar load volume increased 13.1% and 34.7% year-over-year, respectively Second-quarter purchase transactions and purchase dollar volume increased 19.1% and 44.5% year-over-year, respectively Second-quarter total revenues of $6.7 million, a year-over-year increase of $0.2 million or 3.2% Second-quarter plasma revenue of $5.9 million, a year-over-year increase of $1.4 million or 30.1% Second-quarter net loss of $0.9 million, or diluted earnings per share (EPS) of ($0.02) Second-quarter adjusted EBITDA of $0.2 million, or diluted adjusted EBITDA per share of $0.00  Paysign, Inc. (NASDAQ:PAYS), a leading provider of prepaid card programs